The passage of the Patient Protection and Affordable Care Act represents an opportunity to begin repairing parts of our health care system. For example, pharmacists might be able to expand their scope of practice and become more involved with patients and prescribers. However, several roadblocks, including a lack of funding and some ambiguous congressional language, must first be overcome.
You are here
P&T® Journal contents for May 2010
Emphasis on Preventive, Holistic Therapies Offers Possibilities for Pharmacists
Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder
As a first-line therapy for adults and children 6 to 12 years of age for ADHD, LDX is associated with a lower daily average use, less need for augmenting the dose, and better persistence with therapy compared with other long-acting drugs. Dr. Goodman reviews the drug’s history, benefits and risks, labeling for abuse potential, adverse events, and overall safety profile.
Drugs discussed include carglumic acid tablets (Carbaglu) for children and adults with excessive ammonia levels; adapalene topical 0.1% lotion (Differin) for patients with acne vulgaris; and velaglucerase alfa for injection (VPRIV), an enzyme replacement therapy for pediatric and adult patients with type-1 Gaucher disease.
Topics include therapies for blood pressure and lipids in the ACCORD trial, betrixaban versus warfarin for atrial fibrillation, the use of low-osmolar contrast agents in invasive cardiac catheterization, early clopidogrel and eptifibatide for acute coronary syndromes, a new formulation of diazoxide choline for hypertriglyceridemia, and a rosuvastatin/ezetimibe combination for reducing lipid levels.